Gloved hands holding test tube samples in a labGloved hands holding test tube samples in a lab

Our Collaborations and Partnerships

We have entered into strategic collaborations with key industry partners to maintain and expand our global PRAME leadership position and continuously evaluate potential additional value-creating opportunities.

These opportunities enable us to develop transformative therapeutics through the combination of synergistic capabilities and technologies with the goal to make a meaningful impact on the lives of patients together.

SEPTEMBER 2023

Moderna – Research & Development Collaboration

Immatics and Moderna enter strategic research and development collaboration spanning various therapeutic modalities including bispecifics, cell therapy and cancer vaccines.

Read more

Moderna Logo
Editas Medicine Logo
JUNE 2022

Editas Medicine – Research Collaboration

Immatics and Editas Medicine Enter Strategic Collaboration and Licensing Agreement to Combine Gamma Delta T Cell Adoptive Cell Therapies and Gene Editing

Read more

MD Anderson Cancer Cetner The University of Texas Logo
AUGUST 2015

MDACC – Strategic Partnership

Immatics and MD Anderson Announce Launch of Immatics US, Inc., to Develop Multiple T-cell and TCR-based Adoptive Cellular Therapies.

Read more

Contact us about partnering opportunities

Chat bubbles icon
Business Development

E-Mail: partnering@immatics.com

Immatics Biotechnologies GmbH

Paul-Ehrlich-Str. 15–19

72076 Tuebingen